JPMorgan Chase & Co. Issues Pessimistic Forecast for Illumina (NASDAQ:ILMN) Stock Price

Illumina (NASDAQ:ILMN) had its price objective lowered by JPMorgan Chase & Co. from $320.00 to $300.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the life sciences company’s stock. JPMorgan Chase & Co.‘s price target points to a potential upside of 27.12% from the company’s previous close.

Several other equities research analysts have also commented on ILMN. Royal Bank Of Canada increased their price objective on shares of Illumina from $230.00 to $310.00 and gave the company an “outperform” rating in a research note on Monday, October 5th. Citigroup lifted their target price on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Illumina in a research note on Monday, August 31st. Guggenheim upped their target price on Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Finally, Zacks Research lowered Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $238.53.

Illumina Stock Down 18.6%

Shares of NASDAQ ILMN traded down $54.07 during trading on Friday, hitting $235.99. The stock had a trading volume of 5,389,541 shares, compared to its average volume of 2,178,200. Illumina has a 12 month low of $106.12 and a 12 month high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a market capitalization of $35.63 billion, a PE ratio of 44.03, a PEG ratio of 4.09 and a beta of 1.41. The firm has a fifty day moving average of $249.30 and a two-hundred day moving average of $176.18.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.26. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period last year, the firm earned $1.34 earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. As a group, equities research analysts forecast that Illumina will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 2,061,235 shares of company stock worth $436,356,102. 2.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Illumina

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Illumina in the second quarter worth about $3,374,423,000. WCM Investment Management LLC lifted its stake in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA purchased a new stake in shares of Illumina during the 2nd quarter valued at approximately $617,981,000. Janus Henderson Group PLC boosted its holdings in Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock worth $258,924,000 after buying an additional 29,094 shares during the period. Finally, Southpoint Capital Advisors LP boosted its holdings in Illumina by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock worth $258,846,000 after buying an additional 349,536 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.